A5057289859- Cancer, Hypoxia, and Metabolism
- Mitochondrial Function and Pathology
- Pancreatic function and diabetes
- Computational Drug Discovery Methods
- Protein Tyrosine Phosphatases
- Endoplasmic Reticulum Stress and Disease
- Cancer Immunotherapy and Biomarkers
- Cancer Diagnosis and Treatment
- Field-Flow Fractionation Techniques
- Nanoplatforms for cancer theranostics
- Phase Equilibria and Thermodynamics
- Autophagy in Disease and Therapy
- Monoclonal and Polyclonal Antibodies Research
- ATP Synthase and ATPases Research
- Metabolism and Genetic Disorders
- Lung Cancer Treatments and Mutations
- thermodynamics and calorimetric analyses
Université de Lille
2020-2022
Onco Lille
2020
Inserm
2020
CANTHER - Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers
2020
Centre National de la Recherche Scientifique
2020
Centre Hospitalier Universitaire de Lille
2020
UCLouvain
2014-2016
Metastatic progression of cancer is associated with poor outcome, and here we examine metabolic changes underlying this process. Although aerobic glycolysis known to promote metastasis, have now identified a different switch primarily affecting mitochondria. The involves overload the electron transport chain (ETC) preserved mitochondrial functions but increased superoxide production. It provides metastatic advantage phenocopied by partial ETC inhibition, another situation enhanced Both cases...
The binding interactions of PD-1 and PD-L1 have been studied by surface plasmon resonance (SPR) isothermal titration calorimetry (ITC) over the past few years, but these investigations resulted in controversy regarding values dissociation constant (Kd) ( Freeman et al., 2000 ). MST is a powerful new method for quantitative analysis protein-protein (PPIs) with low sample consumption. technique based on movement molecules along microscopic temperature gradients, it detects changes their...
Abstract Immuno-therapy has become a leading strategy to fight cancer. Over the past few years, immuno-therapies using checkpoint inhibitor monoclonal antibodies (mAbs) against programmed death receptor 1 (PD-1) and ligand (PD-L1) have demonstrated improved survival compared with chemotherapy. We describe identification characterization of an innovative series synthetic compounds (named PyrDLones, patented) endowed nanomolar activity PD-L1. PyrDLones properties were characterized several...